135
Participants
Start Date
September 2, 2022
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2023
TQB2450 injection
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
AL2846 capsule
AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
Pemetrexed disodium for injection
Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
Cisplatin injection
Cisplatin is a chemotherapy drug.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Harbin Medical University Cancer Hospital, Harbin
Shandong First Medical University Affiliated Cancer Hospital, Jinan
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Tianjin Medical University General Hospital, Tianjin
The Second Hospital of Tianjin Medical University, Tianjin
Tianjin Chest Hospital, Tianjin
Tianjin Fifth Central Hospital, Tianjin
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Jiangmen Central Hospital, Jiangmen
Affiliated Hospital of Hebei University, Baoding
Inner Mongolia Baotou Steel Hospital, Baotou
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY